Scholarlink

Purpose <p>To study the incidence and subtype of breast cancer in relation to incident and prevalent statin use in a contemporary Swedish prospective cohort, The Karolinska Mammography Project for Risk Prediction of Breast Cancer, KARMA.</p> Methods <p>A total of 35,315 postmenopausal women attending mammography and included in the KARMA cohort (Jan 2011–March 2013) with data on statin use and potential confounders were studied. During eight years of follow-up, 785 incident invasive breast cancer cases were identified.</p> Results <p>A total of 16% of women were prevalent statin users (prior to study inclusion) and 9% were incident statin users (following study inclusion). In multivariable Cox regression analyses, there was no significant association between incident or prevalent statin use and risk of incident breast cancer (HR<sub>adj</sub> 1.24, 95% CI 0.89–1.72, and HR<sub>adj</sub> 0.90, 95% CI 0.73–1.11, respectively). Similarly, no significant association was found for incident or prevalent statin use and subtype-specific risk of breast cancer.</p> Conclusion <p>This prospective population-based study performed in a modern screening population with a substantial number of statin users, concurs with previous publications showing no evidence of an association between statin use and risk of postmenopausal breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Statins and postmenopausal breast cancer risk; results from the KARMA cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月3日

查看全文
  • Marie Klintman,
  • Ann H. Rosendahl,
  • Benjamin R. Johannesen,
  • Deirdre Cronin-Fenton,
  • Mikael Eriksson,
  • Kamila Czene,
  • Per Hall,
  • Signe Borgquist

摘要

Purpose

To study the incidence and subtype of breast cancer in relation to incident and prevalent statin use in a contemporary Swedish prospective cohort, The Karolinska Mammography Project for Risk Prediction of Breast Cancer, KARMA.

Methods

A total of 35,315 postmenopausal women attending mammography and included in the KARMA cohort (Jan 2011–March 2013) with data on statin use and potential confounders were studied. During eight years of follow-up, 785 incident invasive breast cancer cases were identified.

Results

A total of 16% of women were prevalent statin users (prior to study inclusion) and 9% were incident statin users (following study inclusion). In multivariable Cox regression analyses, there was no significant association between incident or prevalent statin use and risk of incident breast cancer (HRadj 1.24, 95% CI 0.89–1.72, and HRadj 0.90, 95% CI 0.73–1.11, respectively). Similarly, no significant association was found for incident or prevalent statin use and subtype-specific risk of breast cancer.

Conclusion

This prospective population-based study performed in a modern screening population with a substantial number of statin users, concurs with previous publications showing no evidence of an association between statin use and risk of postmenopausal breast cancer.